428 related articles for article (PubMed ID: 27357096)
1. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
[TBL] [Abstract][Full Text] [Related]
2. Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers.
Matsunaga T; Kezuka C; Morikawa Y; Suzuki A; Endo S; Iguchi K; Miura T; Nishinaka T; Terada T; El-Kabbani O; Hara A; Ikari A
Biol Pharm Bull; 2015; 38(9):1309-19. PubMed ID: 26328486
[TBL] [Abstract][Full Text] [Related]
3. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Piska K; Koczurkiewicz P; Wnuk D; Karnas E; Bucki A; Wójcik-Pszczoła K; Jamrozik M; Michalik M; Kołaczkowski M; Pękala E
Chem Biol Interact; 2019 Feb; 300():40-48. PubMed ID: 30611789
[TBL] [Abstract][Full Text] [Related]
5. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism.
Zhou F; Hao G; Zhang J; Zheng Y; Wu X; Hao K; Niu F; Luo D; Sun Y; Wu L; Ye W; Wang G
Br J Pharmacol; 2015 Dec; 172(23):5690-703. PubMed ID: 25363561
[TBL] [Abstract][Full Text] [Related]
7. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.
Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE
Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
[TBL] [Abstract][Full Text] [Related]
10. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
11. A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells.
Wang L; Zhang X; Chan JY; Shan L; Cui G; Cui Q; Wang Y; Li J; Chen H; Zhang Q; Yu P; Han Y; Wang Y; Lee SM
J Cell Biochem; 2016 Jan; 117(1):94-105. PubMed ID: 26058377
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
Bose C; Awasthi S; Sharma R; Beneš H; Hauer-Jensen M; Boerma M; Singh SP
PLoS One; 2018; 13(3):e0193918. PubMed ID: 29518137
[TBL] [Abstract][Full Text] [Related]
13. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells.
Mitani T; Ito Y; Harada N; Nakano Y; Inui H; Ashida H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):122-8. PubMed ID: 24975222
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
Schaupp CM; White CC; Merrill GF; Kavanagh TJ
Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
[TBL] [Abstract][Full Text] [Related]
16. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
17. Aidi injection reduces doxorubicin-induced cardiotoxicity by inhibiting carbonyl reductase 1 expression.
Lu Y; Liu W; Lv T; Wang Y; Liu T; Chen Y; Jin Y; Huang J; Zheng L; Huang Y; He Y; Li Y
Pharm Biol; 2022 Dec; 60(1):1616-1624. PubMed ID: 35980105
[TBL] [Abstract][Full Text] [Related]
18. Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells - Involvement of carbonyl reductase 1.
Koczurkiewicz-Adamczyk P; Piska K; Gunia-Krzyżak A; Bucki A; Jamrozik M; Lorenc E; Ryszawy D; Wójcik-Pszczoła K; Michalik M; Marona H; Kołaczkowski M; Pękala E
Eur J Pharm Sci; 2020 Nov; 154():105511. PubMed ID: 32801001
[TBL] [Abstract][Full Text] [Related]
19. Cinnamamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism.
Koczurkiewicz-Adamczyk P; Gąsiorkiewicz B; Piska K; Gunia-Krzyżak A; Jamrozik M; Bucki A; Słoczyńska K; Bojdo P; Wójcik-Pszczoła K; Władyka B; Kołaczkowski M; Pękala E
Life Sci; 2022 Sep; 305():120777. PubMed ID: 35792180
[TBL] [Abstract][Full Text] [Related]
20. AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis.
Syamprasad NP; Jain S; Rajdev B; Panda SR; Gangasani JK; Challa VS; Vaidya JR; Kundu GC; Naidu VGM
Chem Biol Interact; 2023 Aug; 381():110566. PubMed ID: 37257577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
